EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Integrated Microfluidic Giant Magnetoresistance (GMR) Biosensor Platform for Magnetoresistive Immunoassay of Myoglobin

Yikai Wang, Huaiyu Wang, Yunyun Zhang, Shuhui Cui, Fei Hu, Bo'an Li

Biosensors · 2025

DOI: 10.3390/bios16010008 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biosensors, 2025. Verfasst von Yikai Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Science and Technology Research Center of China Customs, Beijing 100026, China. Hauptthemen laut MEDLINE: Myoglobin, Biosensing Techniques. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myocardial infarction (AMI) is a rapidly progressing cardiovascular condition associated with high mortality. Myoglobin is an early biomarker of AMI; however, its detection using conventional methods is limited by complex workflows and low resistance to interference. In this study, we developed an integrated myoglobin detection platform that combined magneto-immunoassay with microfluidic technology. A giant magnetoresistance (GMR) sensor was fabricated using micro-electro-mechanical systems (MEMS). The designed microfluidic chip integrated sample pretreatment, immunoreaction, and magnetic signal capture functionalities. Its built-in GMR sensor, labeled with magnetic nanoparticles, directly converted the “antigen–antibody” biochemical signal into detectable magnetoresistance changes, thereby enabling the indirect detection of myoglobin. A magneto-immunoassay analysis system consisted of a fluidic drive, magnetic field control, and data acquisition functions. Various key parameters were optimized, including EDC/NHS concentration, antibody concentration, and magnetic bead size. Under the optimal conditions and using 1 μm magnetic beads as labels and an external detection magnetic field of 60 Oe, the platform successfully detected myoglobin at 75 ng/mL with ∆MR ≥ 0.202%. Specificity tests demonstrated that the platform had high specificity for myoglobin and could effectively distinguish myoglobin from bovine serum albumin (BSA) and troponin I. This study presents a rapid, accurate myoglobin detection platform that can be applied for the early diagnosis of AMI.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyoglobinBiosensing TechniquesImmunoassayAnimalsMicrofluidicsHumans

Stichwörter der Autor:innen

acute myocardial infarctiongiant magnetoresistance (GMR) sensormagneto-immunoassaymicrofluidic technologymyoglobin

Substanzen

Myoglobin

Autor:innen und Institutionen

  • Science and Technology Research Center of China Customs, Beijing 100026, China.
  • State Key Laboratory for Manufacturing System Engineering, School of Instrument Science and Technology, Xi'an Jiaotong University, Xi'an 710049, China.
  • Department of Clinical Laboratory, The Fifth Medical Center, Chinese People's Liberation Army (PLA) General Hospital, Beijing 100039, China.

Zitieren

APA

Wang, Y., Wang, H., Zhang, Y., Cui, S., Hu, F., & Li, B. (2025). Integrated Microfluidic Giant Magnetoresistance (GMR) Biosensor Platform for Magnetoresistive Immunoassay of Myoglobin. Biosensors. https://doi.org/10.3390/bios16010008

Vancouver

Wang Y, Wang H, Zhang Y, Cui S, Hu F, Li B. Integrated Microfluidic Giant Magnetoresistance (GMR) Biosensor Platform for Magnetoresistive Immunoassay of Myoglobin. Biosensors. 2025. doi:10.3390/bios16010008

BibTeX
@article{Wang2025,
  author = {Wang, Yikai and Wang, Huaiyu and Zhang, Yunyun and Cui, Shuhui and Hu, Fei and Li, Bo'an},
  title = {Integrated Microfluidic Giant Magnetoresistance (GMR) Biosensor Platform for Magnetoresistive Immunoassay of Myoglobin},
  journal = {Biosensors},
  year = {2025},
  doi = {10.3390/bios16010008}
}
Kostenlos starten →